Immune checkpoint inhibitors have ushered in a new era in cancer therapy, although other therapies or combinations thereof are still needed for many patients for whom these drugs are ineffective. In this light, we have identified glypican-3 an HLA-24, HLA-A2 restriction peptide with extreme cancer specificity. In this paper, we summarize results from a number of related clinical trials showing that glypican-3 peptide vaccines induce specific CTLs in most patients (UMIN Clinical Trials Registry: UMIN000001395, UMIN000005093, UMIN000002614, UMN000003696, and UMIN000006357). We also describe the current state of personalized cancer immunotherapy based on neoantigens, and assess, based on our own research and experience, the potential of such therapy to elicit cancer regression. Finally, we discuss the future direction of cancer immunotherapy. shown to have dramatic, long-term antitumor effects. 3, 4 The response rates for immune checkpoint blockers have been as high as 30% for melanoma excluding Hodgkin's lymphoma, with estimates for other cancers ranging from approximately 10% to 30%. However, the development of alternatives for the other 70%-80% of patients for whom this treatment is ineffective continues to be a challenge. To accelerate such development, it is essential to quantify tumor-reactive T cells in an individual patient, and then to encourage such cells to infiltrate cancer tissues. Indeed, it may be necessary to expand the population of tumor-reactive T cells in some patients by, for example, vaccination, adoptive immunotherapy, or similar strategies. Induction of inflammation by adjuvant therapy, chemotherapy, radiation therapy, and other approaches has been reported to promote T-cell infiltration into cancer sites. 5 
| GLYPICAN-3
We first identified GPC3 in August 2001 while searching for novel tumor-associated antigens among several tens of thousands of genes in cDNA microarrays collected by Okabe et al 7 against
cancerous tissues, surrounding non-cancerous tissues, and various normal organs. Glypican-3 was found to be expressed in almost no other normal organs except the embryonal liver and kidney, the placenta in adults, and some renal tubes. However, expression in HCC arising from hepatitis B or C was in both cases 80%
higher than in surrounding non-cancerous tissues. Subsequently, we found that GPC3, a membrane protein, was also secreted, and was a specific and useful marker for HCC. 8 In addition, we have also identified GPC3 peptides that induce specific CTLs, and that have now been tested clinically as cancer vaccines. In the last 15 years, we have yet to encounter a molecule with the same degree of cancer-specific expression and ability to induce CTLs.
Remarkably, Nakano et al also identified GPC3 at around the same time, despite the lack of interaction between our groups.
They have also developed, and continue to develop, antibody therapies targeting GPC3. 10 Strikingly, the protein is nearly absent in all other cancer forms. We note that in some GPC3-positive HCC, a few surrounding normal cells also weakly express GPC3, and we believe that these cells may be involved in recurrence (Figure 1c ).
Based on these characteristics, GPC3 is an ideal target for cancer immunotherapy. Accordingly, we envision an array of GPC3-based strategies, not only as cancer peptide vaccines, but also in antibody therapy, adoptive immunotherapy with TCR-or CAR-transduced T cells, and others. We also anticipate that plasma GPC3 will be validated as a tumor marker for HCC.
| PRECLINICAL STUDIE S OF GPCPEPTIDE VACCINES
The GPC3 peptides in development as cancer vaccines are restricted to HLA-A24 and HLA-A2. Of note, the former is present in approximately 60% of Japanese, whereas the latter is present in 40% of Japanese and is also a major haplotype in Caucacians. 11, 12 Mice immunized with such GPC3 peptides develop antigen-specific CTLs and antitumor activity, but not autoimmune phenomena. 11, 12 In support of subsequent clinical trials, we have completed dose-ranging studies and investigated various adjuvants, including incomplete Freund's adjuvant, CpG, a-GalCel, or aluminum. 13 We found that, (Table 1 ).
14,15
The primary end-points were the safety and immune response.
Dose-limiting toxicity was not observed, even for a single case, in a dose-escalation study of 0.3, 1, 3, 10, and 30 mg. Thus, the maximum tolerated dose was difficult to set. This result also implied that GPC3 peptide vaccines are safe and GPC3 peptide-specific CTL response was shown in 30 patients (90.1%) by IFN-c ELISpot assay.
We reached primary end-points in this study. However, partial clinical response in a patient dosed with 30 mg, as well as dose-dependent immunological reactions, suggested that high doses were more effective. However, a 30-mg dose would also require 6 mL vaccine and thus would entail additional issues in delivery and pain from reddening and duration at injection sites, even though these were generally of low grade. Based on such considerations, we recom- (Table 1) . 16 The primary end-point was GPC3
peptide-specific immune-responses induced by GPC3 peptide vaccination. We note, however, that this trial was initiated after approval of sorafenib as chemotherapy, and patients with late-stage cancer were recruited only after sorafenib was no longer effective. Most of these patients were nearly unresponsive to the vaccine and had progressive disease. Post-vaccination biopsies also proved difficult, and were completed for just 11 cases. Nevertheless, the trial proved informative, with one valuable case in which HCC tissues became inflamed and then necrotic after two injections of the vaccine, despite ongoing liver dysfunction (Figure 2d ). 17 We showed that the present vaccine induced GPC3 peptide-specific CTLs, which were found to infiltrate into the tumor. Moreover, we established GPC3
peptide-specific CTL clones from a tumor biopsy specimen. 16 
| PHASE II CLIN ICAL TRIAL TO INVESTIGATE RELAPSE PREVEN TION FOLLOWING RADICAL TREATMEN T OF H CC
We initiated a single-arm phase II clinical trial (UMIN Clinical Trials Registry: 000002614) to evaluate 1-and 2-year recurrence rates (primary end-point) in 41 patients following radical treatment of HCC, using GPC3 peptide vaccine as adjuvant therapy (Table 1) . 18 Glypican-3 peptide-specific CTL responses were detected in 35 of the 41 patients (85.4%) after vaccination. However, the primary endpoint was not reached for 1-and 2-year recurrence rates. As the absence of GPC3 expression correlates with good prognosis, we limited the control group in this trial strictly to GPC3-negative cases, in order to isolate the effects of GPC3 vaccination post-surgery. Notably, two cases of relapse were observed despite significant numbers of vaccine-induced peptide-specific CTLs in peripheral blood. In these cases, GPC3 was expressed in the primary tumor, but not in the recurrent tumor (Figure 2e ). 18 These results suggest that, although a peptide vaccine against a shared self-antigen may eradicate tumor cells that express such antigen, cancer cells that do not express or lose the same antigen may then proliferate. In such cases, vaccines that target multiple shared antigens would be effective.
One can also anticipate vaccine therapies that target multiple tumorassociated antigens, as will be discussed below. In any case, we strongly expect that further clinical trials will validate the ability of GPC3 peptide vaccines to prevent recurrence after resection of GPC3-positive HCC.
| CLINICAL TRIALS AGAINST OCCC AND REFRACTORY PEDIATRIC CANCER
We also observed antitumor effects in a Nagoya University (Nagoya, Japan) clinical trial (UMIN Clinical Trials Registry: 000003696) of GPC3 peptide vaccines against OCCC (Figure 2f ), 19 highlighting the versatility of this vaccine (Table 1) . 20 The primary end-point was disease control rate at 6 months. In the results, two cases showed partial response one case showed stable disease. The disease control rate at 6 months was 9.4% (3 of the 32 cases). Although response rates (partial response rates) tended to be higher than against HCC, this might be attributable only to the Yellow arrows indicate those lesions. E, In a clinical trial to prevent HCC recurrence after radical treatment, peptide-specific CTLs were detected in peripheral blood after vaccination. However, the cancer relapsed thereafter, and was resected. GPC3 expression was observed in the primary tumor before vaccination, but not in the recurrent tumor. F, Computed tomography scans of a patient with ovarian clear cell carcinoma who responded to GPC3 peptide vaccines. After vaccination, all five metastasis sites became inflamed immediately, and disappeared after five vaccinations. Red arrows indicate those lesions. G, Phase I study in pediatric patients with refractory solid tumors. All five patients with hepatoblastoma in remission at enrollment survived and remained in remission by the end of the study smaller volume of OCCC. We note that OCCCs are extremely recalcitrant to existing anticancer drugs, and effective immunotherapies are eagerly awaited.
As GPC3 expression was also detected in some pediatric cancers, we initiated a clinical trial against GPC3-positive refractory pediatric cancers at the National Cancer Center (Tokyo and Kashiwa, Japan),
St. Luke's International Hospital (Tokyo, Japan), Osaka City General Hospital, (Osaka, Japan) and Kyushu University Hospital (Fukuoka, Japan) (UMIN Clinical Trials Registry: 000006357) ( Table 1) . 21 Eighteen patients with pediatric solid tumors expressing GPC3 underwent GPC3 peptide vaccination. The primary end-point was the incidence of dose-limiting toxicity. In the results, no dose-limiting toxicity was observed. The GPC3 peptide vaccine induced a GPC3-specific CTL response in 7 of the 18 patients (39%), and almost all of the patients showing increased GPC3-specific CTL frequency were in remission and had diagnosed hepatoblastoma. By contrast, GPC3-specific CTL frequency never increased in the refractory advanced progression group. Results from this trial suggest that the vaccine may suppress hepatoblastoma after the second relapse, which is considered to be unavoidable (Figure 2g ). Accordingly, we will continue to aggressively pursue potentially effective therapies and approaches against hepatoblastoma relapse.
| NOVEL APPROACHES TO BOOST THE EFFECTS OF CANCER VACCINES
At present, cancer peptide therapies based on shared self-antigens and that target advanced cancers may have limited efficacy.
Indeed, even if a superior peptide vaccine was developed to abundantly induce peptide-specific CTLs, the effects of such a vaccine would still depend critically on the amount of target peptide presented to HLA class I molecules on cancer cell surfaces. Hence, we initiated preclinical research on intratumor injection of peptide vaccines, 22 and on concurrent therapy with antibodies to PD-1, 23 CD4, 24 and other immunomodulators. These studies indicate that such approaches generally enhance the efficacy of peptide vaccines.
| TH ERAPY WITH GPC3-SPECIFIC CTL CLONES ESTABLISHED FROM VACCINATED PATIENTS
We have successfully established multiple peptide-specific CTL clones from peripheral blood and cancer tissues of patients immunized with GPC3 peptide vaccines during clinical trials (Figure 3) . 14, 16, 25 
MEMBRANE GPC3
GC33, a humanized mAb to GPC3, induces antibody-dependent cell-mediated cytotoxicity against GPC3-positive HCC, as reported in patient-derived xenografted tumors. 26 In a first-in-human phase I trial in the USA among patients with advanced HCC, GC33 was well tolerated, and antitumor effects were observed in some tumors that abundantly expressed GPC3. 27 A similar phase I trial in Japan confirmed the tolerability of GC33, although complete or partial response was not observed. Nevertheless, stable disease was noted in seven of 13 patients, of whom three did not present disease progression beyond 3 months. 28 Currently, GPC3 stratification is determined by immunohistochemistry, and an international phase II trial with placebo is underway. Results from this trial are eagerly awaited. In 2017, the results of fundamental research about ERY974, an anti-GPC3/CD3 bispecific T cell-redirecting antibody, were reported. 29 We would like to expect future clinical applications of this novel drug.
| CHIMERIC AN TIGEN RECEPTOR-TRANSDUCED T-CELL THERAPY AGAINST MEMBRANE GPC3
Although CAR-transduced T-cell therapy elicits remarkable response rates exceeding 80% against blood tumors, its effectiveness has not been established to date against solid carcinomas. Intriguingly, a clinical trial of CAR-transduced T-cell therapy based on GC33 is already underway in China. 30 In a joint project with Tamada et al, Yamaguchi university (Ube, Japan), we are also developing nextgeneration CAR-transduced T-cell therapy against solid carcinomas based on novel GPC3 antibodies. In contrast to traditional modes, we combine cancer-specific antibodies conjugated to FITC with CAR-transduced T cells that react to FITC. 31 In this approach, therapeutic effects could be tightly controlled by the dose of FITC-conjugated antibody, which also maintaining the survival of CARtransduced T cells. Additionally, in collaboration with Kaneko et al,
we are now developing iPS cell-derived GPC3 CAR-T cell therapy (Figure 4 ).
F I G U R E 4 Cancer immunotherapy against glypican-3 (GPC3)
. GPC3 is strongly cancer-specific and extremely promising as a therapeutic target. Existing GPC3 therapies include peptide vaccine therapy and therapy with T cells transduced with a suitable T-cell receptor (TCR). We are presently engaged in developing such T cells from induced pluripotent stem (iPS) cells. Therapies that target membrane-bound GPC3 include antibody therapy and chimeric antigen receptor (CAR)-transduced T-cell therapies, which we are also striving to develop using iPS cells or by other approaches
BASED ON SERUM FULL-LENGTH GPC3
Glypican-3 is subjected to shedding into serum in HCC patients.
Serum GPC3 could be a biomarker for early diagnosis, prediction of recurrence, and assessment of response to anti-GPC3 therapy against HCC. However, such soluble GPC3 protein might block the anti-GPC3 antibody and CAR-T cells. Serum GPC3 could be a treatment effect predictive biomarker or patient eligibility criteria of the anti-GPC3 antibody or anti-GPC3 CAR-T cell therapy. In partnership with a private company, we have developed an assay to quantify serum full-length GPC3, which we have shown to be predictive of HCC recurrence after surgery. 32 In any case, we continue to investigate the value of this assay in early diagnosis, as well as in the prediction and assessment of response to anti-GPC3 therapy. 59 In recent issues of Nature, clinical trials were described to prevent post-resection recurrence of advanced melanoma using cancer vaccines targeting neoantigens. One report was of a vaccine using a long peptide, 60 and another was of an RNA vaccine. 61 In both trials, T-cell activation was consistently reported, along with relapse prevention. In cases of relapse, anti-PD-1 proved effective. Similarly, we have carried out exome sequencing and HLA-binding prediction for lung, hepatic-biliary-pancreatic, and gynecologic cancers, and are currently developing a cancer vaccine based on predicted, personalized neoantigenic peptides. We expect that studies of personalized cancer vaccines will be launched in Japan in the future.
| NE OAN TIGENS

| ADOPTIVE IMMUNOTHERAPY AGAINST NE OAN TIGENS
Rosenberg et al have also identified TCRs that recognize neoantigens, and are now striving to develop personalized cancer immunotherapy using T cells transduced with such TCRs, although it is still not clear whether T cells that recognize neoantigens or shared antigens accumulate in tumors. Under current investigation is whether adoptive immunotherapy with TILs, found to be effective against melanoma, is also effective against other solid carcinomas.
Moreover, we are currently developing a high-throughput system to isolate multiple tumor-reactive populations from TILs in individual patients, as it is essential to identify T cells and TCRs that effectively eliminate carcinoma as speedily as possible.
We seek to develop adoptive immunotherapy with such T cells, but transduced with individual TCRs identified from TILs in patients.
To this end, we are identifying antigens that react with individual TCRs, concurrent with our efforts to develop cancer vaccines that target neoantigens. In addition, we are isolating T cells that recognize shared antigens such as GPC3 or neoantigens unique to an individual, and that are also dominant in the tumor tissue ( Figure 5 ). 
| FUTURE PER SPECTIVE S
